7 results

• Subsys Lawsuits May Force Opioid Manufacturer Into Bankruptcy, Company Warns

  May 13, 2019

  Irvin Jackson

  The makers of the painkiller Subsys say they may declare bankruptcy due to the rising costs of litigation, just days after the founder and several former executives were found guilty of racketeering charges.

• Walgreens, CVS Face Lawsuit Over Opioid Crisis Filed By Florida Attorney General

  November 21, 2018

  Irvin Jackson

  Florida accuses Insys, Walgreens and CVS of contributing to the national opioid drug crisis.

• Doctors Rewarded By Drug Companies Prescribe More Opioids: Study

  May 15, 2018

  Martha Garcia

  A new study finds a link between payments from opioid manufacturers, and doctors who prescribe more of the painkillers than their peers.

• SubSys Problems Result in Investigation Over Painkiller Marketing By Arizona AG

  June 27, 2017

  Irvin Jackson

  Arizona has joined a number of other states who are investigating the sales and marketing tactics of the fentanyl-spray painkiller SubSys, which many say was purposefully sold to patients who did not qualify for the powerful drug.

• FBI Seeks Subsys Users As Criminal Investigation Over Sales Tactics, Additions, Continues

  June 20, 2017

  Irvin Jackson

  A number of Subsys lawsuits have been filed as the FBI continues to investigate criminal claims that the manufacturer bribed doctors to sell the fentanyl spray to patients who did not need it and were likely to get addicted.

• Subsys Purposefully Sold To Pain Patients That Did Not Need It: Whistleblower

  June 6, 2017

  Irvin Jackson

  Former employees accuse the makers of Subsys, a powerful painkiller, of telling them to lie to insurance companies to boost sales of the drug, which was supposed to be restricted to cancer patients.

• Suspicious Subsys Fentanyl Sales Lead to Illegal Marketing Investigation

  May 15, 2014

  Irvin Jackson

  The drug maker Insys faces an investigation over possible illegal marketing of their new fentanyl spray Subsys, amid concerns about mounting sales for the niche drug and questions about incentives for sales representatives.